DOCSLIB.ORG

1 Hyperactive Mtor Induces Neuroendocrine Differentiation in Prostate Cancer Cell

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Hyperactive Mtor Induces Neuroendocrine Differentiation in Prostate Cancer Cell 1 Hyperactive mTOR Induces Neuroendocrine Differentiation in Prostate Cancer Cell 2 with Concurrent Up-regulation of IRF1 3 4 Authors: Mayuko Kanayama1, 2, Toshiya Hayano3, Michinori Koebis2, Tatsuya Maeda4, Yoko 5 Tabe5, Shigeo Horie1, and Atsu Aiba2 6 7 Affiliations: 1Department of Urology, Juntendo University Graduate School of Medicine, 8 Tokyo, Japan, 2Laboratory of Animal Resources, Center for Disease Biology and Integrated 9 Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 10 3Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, 11 Shiga, Japan, 4Institute of Molecular and Cellular Biosciences, The University of Tokyo, 12 Tokyo, Japan, 5Department of Clinical Laboratory Medicine, Juntendo University Graduate 13 School of Medicine, Tokyo, Japan. 14 Correspondence: Atsu Aiba, Laboratory of Animal Resources, Center for Disease Biology 15 and Integrated Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 16 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. Tel: +81-3-5841-3638, Fax: +81-3-5841-3679, 17 E-mail: [email protected] 18 The running title: The role of IRF1 in active mTOR-induced NED 19 This work was supported in part by a Grant-in-Aid for Scientific Research on Innovative 20 Areas (Comprehensive Brain Science Network), Grant Numbers 221S0003 (to A.A.), and 21 Grant-in-Aid for Scientific Research (B), JSPS KAKENHI Grant Numbers 25291042 and 22 17H03802 (to T.M.) from the Ministry of Education, Science, Sports and Culture of Japan. 23 Disclosure of Potential Conflicts of Interest: The authors have no conflict of interest. 1 1 Abstract 2 BACKGROUND 3 Neuroendocrine-differentiated prostate cancer (NEPCa) is refractory to androgen deprivation 4 therapy and shows a poor prognosis. The underlying mechanisms responsible for 5 neuroendocrine differentiation (NED) are yet to be clarified. In this study, we investigated the 6 role of mammalian target of rapamycin (mTOR) in NEPCa. 7 METHODS 8 We utilized a gain-of-function analysis by establishing a human PCa LNCaP stable line that 9 expresses hyperactive mTOR (LNCaP-mTOR). Then, we employed a comprehensive mass 10 spectrometric analysis to identify a key transcription factor in LNCaP-mTOR, followed by a 11 loss-of-function analysis using CRISPR/Cas system. 12 RESULTS 13 The activation of mTOR induced NED. We observed significant cell growth arrest in NED of 14 LNCaP-mTOR, which accompanied increased expression of p21WAF1/CIP1. A comprehensive 15 mass spectrometric analysis identified interferon regulatory factor 1 (IRF1) as a key 16 transcription factor in growth arrest of LNCaP-mTOR. The disruption of IRF1 gene in 17 LNCaP-mTOR reversed cell growth arrest along with the suppression of its target p21WAF1/CIP1. 18 These results indicate that the growth arrest in NED is at least in part dependent on IRF1 19 through the induction of p21WAF1/CIP1. 20 CONCLUSIONS 21 We identified active mTOR as a novel inducer of NED, and elucidated a mechanism 22 underlying the malignant transformation of NEPCa by recapitulating NED in vitro. 23 Keywords: Hyperactive mTOR, Interferon Regulatory Factor 1, LNCaP, NED 2 1 1 INTRODUCTION 2 To date, several reports have suggested that neuroendocrine (NE) differentiation (NED) is 3 responsible for progression of prostate cancer (PCa) to hormone-refractory state.1-3 4 NE-differentiated PCa (NEPCa) is thought to accelerate PCa progression through several 5 mechanisms.2,4,5 Nevertheless, the underlying mechanisms responsible for NED development 6 are yet to be fully clarified. 7 Meanwhile, the activation of the PI3K/Akt/mTOR pathway is a frequent event in many types 8 of cancers including PCa, such as PTEN deletion and activating mutations in PIK3CA.6 9 Interestingly, the activation of mTOR pathway has been reported in NE tumors of other 10 tissues.7,8 Thus, we hypothesized that activation of mTOR may induce NED in PCa as well. 11 To prove this hypothesis and investigate the molecular mechanisms of NEPCa progression, 12 we performed a gain-of-function analysis by establishing a PCa stable line that expresses 13 hyperactive mTOR. 14 Here, we demonstrate that hyperactive mTOR induces NED in LNCaP with matching 15 phenotypes reported earlier including the growth arrest,9-16and this growth arrest is at least in 16 part dependent on interferon regulator factor 1 (IRF1) through the induction of p21WAF1/CIP1. 17 In LNCaP stably expressing hyperactive mTOR (LNCaP-mTOR), we focused on IRF1 18 based on the results of a comprehensive proteomic analysis. Furthermore, IRF1 knockout in 19 LNCaP-mTOR by CRISPR/Cas system resulted in a partial recovery from growth arrest. 20 Together, we elucidated the mechanism underlying the malignant transformation of NED by 21 generating two types of NED models in vitro depending on IRF1 gene status. 3 1 2 MATERIALS AND METHODS 2 2.1 Generation of a stable line expressing active mTOR with the Tet-On 3G system 3 The tetracycline-inducible (Tet-on) 3G bidirectional expression system was purchased from 4 Clontech (Montain View, CA, USA). A stable line that expresses EGFP and active mTOR 5 upon doxycycline (Dox, Sigma-Aldrich, St. Louis, MO, USA) administration 6 (LNCaP-mTOR) was generated in accordance with the manufacturer’s protocol. 7 2.2 Cell lines and cell culture 8 The human PCa cell line LNCaP was purchased from RIKEN BRC (Tsukuba, Japan) cell 9 bank. LNCaP was maintained in the RPMI 1640 medium supplemented with 10% FBS and 10 1×Penicillin-Streptomycin-Glutamine (Gibco, Walthman, MA, USA). When antibiotics were 11 used for selection or induction, they were added to the medium at the following 12 concentrations: G418 at 500 μg/mL for selection and at 100 μg/mL for maintenance, 13 puromycin at 0.25 μg/mL for both selection and maintenance, hygromycin at 100~125 μg/mL 14 for both selection and maintenance, and Dox at 1 μg/mL for induction of the Tet-On system. 15 For the inhibition of mTOR pathway, cells were incubated with an mTOR inhibitor, 16 rapamycin (Cell Signaling Technology (CST), Danvers, MA, USA), for 7 days at 17 concentrations of 100 nM, 10 nM, 1 nM, or 0.1 nM. For cell counting, 4.6×105 cells of 18 LNCaP were seeded into one dish with or without Dox. The number of cells was counted 19 manually with a hemocytometer. 20 2.3 Xenotransplantation of LNCaP-mTOR and immunohistochemical analysis 21 Experimental procedures were approved by the Institutional Animal Care and Use Committee 22 of the University of Tokyo (Permit Number: M-P14-011). Eight NOD/SCID mice at 7 weeks 23 of age were subcutaneously implanted with 1.0×107 LNCaP-mTOR suspended in Matrigel 24 HC (Corning, New York, USA) at one site of each flank. Mice were given either 1 mg/mL 25 Dox or pure water. After 4~6 months, when tumors became palpable (100 mg~1 g in wet 4 1 weight), animals were euthanized and tumors were excised. Rapamycin was administrated at 2 a dose of 2 mg/kg every other day by intraperitoneal injection for 1 month after tumors 3 became palpable, during which oral Dox administration was continued. For a histological 4 analysis, excised tumors were fixed with 4% formaldehyde, then, paraffin sections were made 5 in accordance with standard protocols. Antibodies used for immunohistochemistry were 6 anti-phospho-S6 ribosomal protein Ser235/236 (1:200; CST 2211), anti-NSE (1:200; a gift 7 from Dr. Sakimura at Niigata University) and anti-chromogranin A (1:100; ab15160, from 8 abcam, Cambridge, UK). The staining was developed with DAB substrate. 9 2.4 Analysis of cellular morphology 10 Phase-contrast images of cells were acquired with a light microscope (BZ 8000 KEYENCE, 11 Osaka, Japan). For quantification of the length of cellular processes and the number of 12 processes, phase-contrast images of LNCaP-mTOR cultured with or without Dox were taken on 13 Day 7. For randomly chosen 20 cells, the sum of length of processes and branches stemming 14 from one cell was calculated, and the number of processes per cell was counted, using image-J 15 software. The results were compared by two-tail paired t-test. Also, in order to investigate the 16 effects of Dox withdrawal from Dox-treated cells, LNCaP-mTOR was cultured with Dox for 17 one week, followed by Dox withdrawal from the medium. GFP emission and cellular 18 morphology were serially observed with a microscope. 19 For electron microscopic images, cells were fixed with 2.5% glutaraldehyde in 0.1 M PB for 1 20 h at 4℃, followed by incubation with 1% osmium in 0.1 M PB for 1 h at 4℃. After dehydration 21 with ethanol, embedding in Epon (Epok 812, Okenshoji, Tokyo, Japan) was done in accordance 22 with routine protocols. Thin sections (80 nm) were cut with glass or diamond knife and picked 23 up on grid mesh. Sections were stained with uranyl acetate for 30 min at room temperature, 24 followed by staining with lead citrate for 3 min. Images were captured with a scanning electron 25 microscope (Hitachi HT 7700, Tokyo, Japan). 5 1 2.5 RNA extraction and RT-PCR analysis 2 Total RNA was isolated from cells with TRIzol reagent (Invitrogen, Walthman, MA, USA). 3 Extracted RNA was converted to cDNA using RNA PCR Kit AMV Ver.3.0 (TaKaRa, Shiga, 4 Japan). The equal amount of cDNA was PCR-amplified with TaKaRa Ex Taq. The primer sets 5 used were as follows: the primer pair for IRF1: 5’-AATTCCAACCAAATCCCGGGG-3’ and 6 5’-AGGCATCCTTGTTGATGTCCCAG-3’, IRF6: 5’-GTGCCCATGAACCCAGTGAAG-3’ 7 and 5’-CTGATCCAGCTCATCTTCCTCATC-3’, interferon (IFN)-β: 5’-AGCACTGG 8 CTGGAATGAGACTATTG-3’ and 5’-ACTGCTCATGAGTTTTCCCCTGG-3’, GAPDH: 9 5’-AGCACCAGGTGGTCTCCTC-3’ and 5’-CCCTGTTGCTGTAGCCAAATTC-3’.
Load more

Recommended publications
  • DEPARTMENT of PUBLIC HEALTH and ENVIRONMENT 1 Laboratory
    Document 2 HRG Page 46 of 48 1 DEPARTMENT OF PUBLIC HEALTH AND ENVIRONMENT 2 Laboratory Services Division 3 NEWBORN SCREENING AND SECOND NEWBORN SCREENING 4 5 CCR 1005-4 5 Adopted by the Board of Health on _______________; effective ______________. 6 _________________________________________________________________________ 7 ***** 8 SECTION 2: NEWBORN SCREENING REQUIREMENTS FOR NAMED SUBMITTERS 9 ***** 10 2.4 List of Conditions for Newborn Screening 11 The Laboratory shall conduct screening tests for the following conditions: 12 2.4.1 Phenylketonuria 13 2.4.2 Congenital Hypothyroidism 14 2.4.3 Hemoglobinopathies 15 2.4.4 Galactosemia 16 2.4.5 Cystic Fibrosis 17 2.4.6 Biotinidase Deficiency 18 2.4.7 Congenital Adrenal Hyperplasia 19 2.4.8 Medium Chain Acyl-CoA Dehydrogenase Deficiency 20 2.4.9 Very Long Chain Acyl-CoA Dehydrogenase Deficiency 21 2.4.10 Long-Chain L-3-Hydroxy Acyl-CoA Dehydrogenase Deficiency 22 2.4.11 Trifunctional Protein Deficiency 23 2.4.12 Carnitine Acyl-Carnitine Translocase Deficiency 24 2.4.13 Short Chain Acyl-CoA Dehydrogenase Deficiency 25 2.4.14 Carnitine Palmitoyltransferase II Deficiency 26 2.4.15 Glutaric Acidemia Type 2 27 2.4.16 Arginosuccinic Acidemia 28 2.4.17 Citrullinemia Document 2 HRG Page 47 of 48 29 2.4.18 Tyrosinemia 30 2.5.19 Hypermethionemia 31 2.4.20 Maple Syrup Urine Disease 32 2.4.21 Homocystinuria 33 2.4.22 Isovaleric Acidemia 34 2.4.23 Glutaric Acidemia Type 1 35 2.5.24 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency 36 2.4.25 Multiple Carboxylase Deficiency 37 2.4.26 3-Methylcrotonyl-CoA
    [Show full text]
  • Identification of the Binding Partners for Hspb2 and Cryab Reveals
    Brigham Young University BYU ScholarsArchive Theses and Dissertations 2013-12-12 Identification of the Binding arP tners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non- Redundant Roles for Small Heat Shock Proteins Kelsey Murphey Langston Brigham Young University - Provo Follow this and additional works at: https://scholarsarchive.byu.edu/etd Part of the Microbiology Commons BYU ScholarsArchive Citation Langston, Kelsey Murphey, "Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins" (2013). Theses and Dissertations. 3822. https://scholarsarchive.byu.edu/etd/3822 This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected], [email protected]. Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston A thesis submitted to the faculty of Brigham Young University in partial fulfillment of the requirements for the degree of Master of Science Julianne H. Grose, Chair William R. McCleary Brian Poole Department of Microbiology and Molecular Biology Brigham Young University December 2013 Copyright © 2013 Kelsey Langston All Rights Reserved ABSTRACT Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactors and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston Department of Microbiology and Molecular Biology, BYU Master of Science Small Heat Shock Proteins (sHSP) are molecular chaperones that play protective roles in cell survival and have been shown to possess chaperone activity.
    [Show full text]
  • Reactome | Metabolism of Amino Acids and Derivatives (R-HSA-71291)
    Metabolism of amino acids and derivatives D'Eustachio, P., Gopinathrao, G., Ito, S., Jassal, B., Jupe, S., Rush, MG., Stephan, R., Williams, MG., d'Ischia, M. European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University. The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of Creative Commons Attribution 4.0 Inter- national (CC BY 4.0) License. For more information see our license. 06/08/2021 Introduction Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross- referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics research- ers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioin- formaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways. The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program). Literature references Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway ana- lysis: a high-performance in-memory approach. BMC bioinformatics, 18, 142.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • PROTEOMIC ANALYSIS of HUMAN URINARY EXOSOMES. Patricia
    ABSTRACT Title of Document: PROTEOMIC ANALYSIS OF HUMAN URINARY EXOSOMES. Patricia Amalia Gonzales Mancilla, Ph.D., 2009 Directed By: Associate Professor Nam Sun Wang, Department of Chemical and Biomolecular Engineering Exosomes originate as the internal vesicles of multivesicular bodies (MVBs) in cells. These small vesicles (40-100 nm) have been shown to be secreted by most cell types throughout the body. In the kidney, urinary exosomes are released to the urine by fusion of the outer membrane of the MVBs with the apical plasma membrane of renal tubular epithelia. Exosomes contain apical membrane and cytosolic proteins and can be isolated using differential centrifugation. The analysis of urinary exosomes provides a non- invasive means of acquiring information about the physiological or pathophysiological state of renal cells. The overall objective of this research was to develop methods and knowledge infrastructure for urinary proteomics. We proposed to conduct a proteomic analysis of human urinary exosomes. The first objective was to profile the proteome of human urinary exosomes using liquid chromatography-tandem spectrometry (LC- MS/MS) and specialized software for identification of peptide sequences from fragmentation spectra. We unambiguously identified 1132 proteins. In addition, the phosphoproteome of human urinary exosomes was profiled using the neutral loss scanning acquisition mode of LC-MS/MS. The phosphoproteomic profiling identified 19 phosphorylation sites corresponding to 14 phosphoproteins. The second objective was to analyze urinary exosomes samples isolated from patients with genetic mutations. Polyclonal antibodies were generated to recognize epitopes on the gene products of these genetic mutations, NKCC2 and MRP4. The potential usefulness of urinary exosome analysis was demonstrated using the well-defined renal tubulopathy, Bartter syndrome type I and using the single nucleotide polymorphism in the ABCC4 gene.
    [Show full text]
  • Glycine and Serine Inhibition of D-Glycerate Dehydrogenase and 3-Phosphoglycerate Dehydrogenase of Rat Brain
    Volume 17, number 1 FEBS LETTERS September 1971 GLYCINE AND SERINE INHIBITION OF D-GLYCERATE DEHYDROGENASE AND 3-PHOSPHOGLYCERATE DEHYDROGENASE OF RAT BRAIN M.L. UHR and M.K. SNEDDON Department of Physiology, Australian National University, Canberra, A.C. T. 2601, Australia Received 16 July 1971 1. Introduction 2. Materials and methods Glycine is probably a major inhibitory transmitter Barium phosphoglycerate and calcium DL-glycer- in the mammalian central nervous system [ 1,2] . ate purchased from Sigma Chemical Corporation, were Hence the metabolism and metabolic control of converted to sodium salts by passage through a glycine could be important for the efficient function- column of Dowex-SO(H?) and neutralization of the ing of nervous tissue, particularly of the spinal cord. emerging acids. Phosphoglycerate concentration was As glycine may be formed from serine by serine estimated by the method of Czok and Eckert [7]. hydroxymethylase (EC 2.1.2.1) [3] , enzymes neces- Glycerate was estimated by the method of Bartlett sary for the formation of serine from carbohydrate [8] with the concentration of chromotrophic acid sources could be important for the production and raised to 0.025% as recommended by Dawkins and regulation of glycine. Two major pathways of serine Dickens [9] . NAD was purchased from P-L Biochemi- formation have been described in mammalian sys- cals, and NADP from Sigma. tems, the “phosphoryl:ted” pathway from 3-phos- Rat cortical tissue was homogenized in 0.32 M phoglycerate [4], and the “non-phosphorylated” sucrose containing 0.5 mM dithiothreitol (DTT) and pathway from D-glycerate [5,6]. We decided there- centrifuged at 105,000 g for 100 min.
    [Show full text]
  • Material Data Sheet
    MATERIAL DATA SHEET Recombinant Human His6 UBE2N/UBE2V2 Complex Cat. # E2­666 Ubiquitin conjugating Enzyme E2N (UBE2N), also known as Ubiquitin conjugating Enzyme 13 (Ubc13), forms a functional complex with the catalytically inactive UBE2V2 (human homologue of yeast MMS2) protein (1). Human UBE2N/Ubc13 shares 100% and 99% amino acid (aa) sequence identity with the mouse and rat orthologs, respectively, while human UBE2V2 shares 99% aa sequence identity with its mouse and rat orthologs. The UBE2N/UBE2V2 Complex functions with Ubiquitin ligases (E3s), including RNF111 and RNF8, to synthesize Lys63­linked Ubiquitin chains (2,3) that can either be unanchored or attached to target proteins (4, 5). The UBE2N/UBE2V2 complex has important roles in facilitating responses to various forms of DNA damage (2, 6). Product Information Quantity: 100 µg | 50 µg MW: 18 kDa (UBE2N), 17 kDa (UBE2V2) Source: E. coli­derived Contains an N­terminal 6­His tag Accession # P61088 (UBE2N)/Q15819 (UBE2V2) Stock: 0.88 mg/ml (25 μM) in 50 mM HEPES pH 7.5, 200 mM NaCl, 10% Glycerol (v/v), 2 mM TCEP Purity: >95%, by SDS­PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain. Rev. 5/22/2014 Page 1 of 2 www.bostonbiochem.com Boston Biochem products are available via the R&D Systems distributor network. USA & CANADA Tel: (800) 343-7475 EUROPE Tel: +44 (0)1235 529449 CHINA Tel: +86 (21) 52380373 Use & Storage Use: Recombinant Human His6­UBE2N/UBE2V2 Complex is a member of the Ubiquitin conjugating (E2) enzyme family that receives Ubiquitin from a Ubiquitin activating (E1) enzyme and subsequently interacts with a Ubiquitin ligase (E3) to conjugate Ubiquitin to substrate proteins.
    [Show full text]
  • The Ubiquitination Enzymes of Leishmania Mexicana
    The ubiquitination enzymes of Leishmania mexicana Rebecca Jayne Burge Doctor of Philosophy University of York Biology October 2020 Abstract Post-translational modifications such as ubiquitination are important for orchestrating the cellular transformations that occur as the Leishmania parasite differentiates between its main morphological forms, the promastigote and amastigote. Although 20 deubiquitinating enzymes (DUBs) have been partially characterised in Leishmania mexicana, little is known about the role of E1 ubiquitin-activating (E1), E2 ubiquitin- conjugating (E2) and E3 ubiquitin ligase (E3) enzymes in this parasite. Using bioinformatic methods, 2 E1, 13 E2 and 79 E3 genes were identified in the L. mexicana genome. Subsequently, bar-seq analysis of 23 E1, E2 and HECT/RBR E3 null mutants generated in promastigotes using CRISPR-Cas9 revealed that the E2s UBC1/CDC34, UBC2 and UEV1 and the HECT E3 ligase HECT2 are required for successful promastigote to amastigote differentiation and UBA1b, UBC9, UBC14, HECT7 and HECT11 are required for normal proliferation during mouse infection. Null mutants could not be generated for the E1 UBA1a or the E2s UBC3, UBC7, UBC12 and UBC13, suggesting these genes are essential in promastigotes. X-ray crystal structure analysis of UBC2 and UEV1, orthologues of human UBE2N and UBE2V1/UBE2V2 respectively, revealed a heterodimer with a highly conserved structure and interface. Furthermore, recombinant L. mexicana UBA1a was found to load ubiquitin onto UBC2, allowing UBC2- UEV1 to form K63-linked di-ubiquitin chains in vitro. UBC2 was also shown to cooperate with human E3s RNF8 and BIRC2 in vitro to form non-K63-linked polyubiquitin chains, but association of UBC2 with UEV1 inhibits this ability.
    [Show full text]
  • WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, C12Q 1/68 (2018.01) A61P 31/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, C12Q 1/70 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2018/056167 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 16 October 2018 (16. 10.2018) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/573,025 16 October 2017 (16. 10.2017) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (71) Applicant: MASSACHUSETTS INSTITUTE OF MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TECHNOLOGY [US/US]; 77 Massachusetts Avenue, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Cambridge, Massachusetts 02139 (US).
    [Show full text]
  • Monoclonal Anti-Human Adipon
    monocl AAD0602 Monoclonal anti-adiponectin antibody (clone 1G12) 100ul 311-Eur ATGen onal monocl AAD0602 Monoclonal anti-adiponectin antibody (clone 1G12) 50ul 227-Eur ATGen onal monocl AAD0614 Monoclonal anti-human adiponectin antibody (clone 5H7) 100ul 311-Eur ATGen onal monocl AAD0614 Monoclonal anti-human adiponectin antibody (clone 5H7) 50ul 227-Eur ATGen onal monocl AAK0604 Monoclonal anti-human AK3 antibody (clone SJB3-36) 100ul 354-Eur ATGen onal monocl AAK0604 Monoclonal anti-human AK3 antibody (clone SJB3-36) 50ul 252-Eur ATGen onal monocl AAP0501 Monoclonal anti-human ANGPTL3 antibody (clone 1D10 ) 100ul 284-Eur ATGen onal monocl AAP0501 Monoclonal anti-human ANGPTL3 antibody (clone 1D10 ) 50ul 191-Eur ATGen onal monocl AAP0501 Monoclonal anti-human ANGPTL3 antibody (clone 1D10) 100ul 311-Eur ATGen onal monocl AAP0501 Monoclonal anti-human ANGPTL3 antibody (clone 1D10) 50ul 227-Eur ATGen onal monocl AAP0836 Monoclonal anti-human APP antibody (clone J4H9) 100ul 311-Eur ATGen onal monocl AAP0836 Monoclonal anti-human APP antibody (clone J4H9) 50ul 227-Eur ATGen onal monocl ABH0708 Monoclonal anti-human BHMT antibody (clone 3D6 ) 100ul 284-Eur ATGen onal monocl ABH0708 Monoclonal anti-human BHMT antibody (clone 3D6 ) 50ul 191-Eur ATGen onal monocl ABH0708 Monoclonal anti-human BHMT antibody (clone 3D6) 100ul 311-Eur ATGen onal monocl ABH0708 Monoclonal anti-human BHMT antibody (clone 3D6) 50ul 227-Eur ATGen onal monocl ABI0923 Monoclonal anti-human BID antibody (clone 4D3) 100ul 284-Eur ATGen onal monocl ABI0923 Monoclonal anti-human
    [Show full text]
  • Multiple Acyl-Coa Dehydrogenase Deficiency with Variable
    G C A T T A C G G C A T genes Article Multiple Acyl-CoA Dehydrogenase Deficiency with Variable Presentation Due to a Homozygous Mutation in a Bedouin Tribe Orna Staretz-Chacham 1,2,* , Shirly Amar 3, Shlomo Almashanu 4, Ben Pode-Shakked 5,6, Ann Saada 7,8 , Ohad Wormser 9 and Eli Hershkovitz 2,10 1 Metabolic Clinic, Pediatric Division, Soroka University Medical Center, Beer Sheva 84101, Israel 2 Faculty of Health Sciences, Ben-Gurion University, Beer Sheva 84101, Israel; [email protected] 3 Genetic Lab, Soroka University Medical Center, Beer Sheva 84101, Israel; [email protected] 4 National Newborn Screening Program, Ministry of Health, Tel-HaShomer, Ramat Gan 52621, Israel; [email protected] 5 Metabolic Disease Unit, Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Tel-Hashomer, Ramat Gan 52621, Israel; [email protected] 6 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 39040, Israel 7 Hadassah Medical Center, Department of Genetics, Jerusalem 911201, Israel; [email protected] 8 Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 911201, Israel 9 The Morris Kahn Laboratory of Human Genetics, National Institute for Biotechnology in the Negev and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84101, Israel; [email protected] 10 Department of Pediatrics D, Soroka Medical Center, Beer Sheva 84101, Israel * Correspondence: [email protected]; Tel.: +972-545-713-191 Abstract: Multiple acyl-CoA dehydrogenase deficiency (MADD) is a fatty acid and amino acid Citation: Staretz-Chacham, O.; Amar, oxidation defect caused by a deficiency of the electron-transfer flavoprotein (ETF) or the electron- S.; Almashanu, S.; Pode-Shakked, B.; transfer flavoprotein dehydrogenase (ETFDH).
    [Show full text]
  • Annual Symposium of the Society for the Study of Inborn Errors of Metabolism Birmingham, UK, 4 – 7 September 2012
    J Inherit Metab Dis (2012) 35 (Suppl 1):S1–S182 DOI 10.1007/s10545-012-9512-z ABSTRACTS Annual Symposium of the Society for the Study of Inborn Errors of Metabolism Birmingham, UK, 4 – 7 September 2012 This supplement was not sponsored by outside commercial interests. It was funded entirely by the SSIEM. 01. Amino Acids and PKU O-002 NATURAL INHIBITORS OF CARNOSINASE (CN1) O-001 Peters V1 ,AdelmannK2 ,YardB2 , Klingbeil K1 ,SchmittCP1 , Zschocke J3 3-HYDROXYISOBUTYRIC ACID DEHYDROGENASE DEFICIENCY: 1Zentrum für Kinder- und Jugendmedizin de, Heidelberg, Germany IDENTIFICATION OF A NEW INBORN ERROR OF VALINE 2Universitätsklinik, Mannheim, Germany METABOLISM 3Humangenetik, Innsbruck, Austria Wanders RJA1 , Ruiter JPN1 , Loupatty F.1 , Ferdinandusse S.1 , Waterham HR1 , Pasquini E.1 Background: Carnosinase degrades histidine-containing dipeptides 1Div Metab Dis, Univ Child Hosp, Amsterdam, Netherlands such as carnosine and anserine which are known to have several protective functions, especially as antioxidant agents. We recently Background, Objectives: Until now only few patients with an established showed that low carnosinase activities protect from diabetic nephrop- defect in the valine degradation pathway have been identified. Known athy, probably due to higher histidine-dipeptide concentrations. We deficiencies include 3-hydroxyisobutyryl-CoA hydrolase deficiency and now characterized the carnosinase metabolism in children and identi- methylmalonic semialdehyde dehydrogenase (MMSADH) deficiency. On fied natural inhibitors of carnosinase. the other hand many patients with 3-hydroxyisobutyric aciduria have been Results: Whereas serum carnosinase activity and protein concentrations described with a presumed defect in the valine degradation pathway. To correlate in adults, children have lower carnosinase activity although pro- identify the enzymatic and molecular defect in a group of patients with 3- tein concentrations were within the same level as for adults.
    [Show full text]